Last day of trading of SPEC TO3 subscription warrants tomorrow, Nov. 27
The last day of trading of SpectraCure AB (publ) TO3 is Wednesday, November 27th, 2019.
Subscription of shares supported by the warrants in the TO3 program, implies that every two (2) warrants entitles the holder to subscribe for one (1) new share in SpectraCure at the subscription price of SEK 6.50.
If all warrants are fully exercised, the company cash position will increase by a total of approximately MSEK 37.1 MSEK after deduction of related issue costs.
For further information, contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90
Certified Adviser is G&W Fondkommission, e-mail: firstname.lastname@example.org, phone: +46-(8)-503 000 50.
SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region.